Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01784861
Recruitment Status : Active, not recruiting
First Posted : February 6, 2013
Last Update Posted : July 18, 2019
Sponsor:
Collaborator:
Tyrogenex
Information provided by (Responsible Party):
Washington University School of Medicine

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : December 31, 2019
Estimated Study Completion Date : December 31, 2019